Serum substance P concentration in pneumonia patients with chronic schizophrenia

International Medical Journal

Volumn 16, Issue 3, 2009, Pages 181-182

  Nagamine, Takahiko ^a   Nakayama, Hiroto ^a  

^a Seiwakai Kitsunan Hospital   (Japan)

Author keywords

Pneumonia; Schizophrenia; Substance P; Typical antipsychotics

Indexed keywords

NEUROLEPTIC AGENT; SUBSTANCE P;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; MALE; PNEUMONIA; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RADIOIMMUNOASSAY; RISK ASSESSMENT; SCHIZOPHRENIA; THORAX RADIOGRAPHY;

EID: 70350162232     PISSN: 13412051     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Kuehn BM. FDA warns antipsychotic drugs may be risky for elderly. JAMA 2005; 293: 2462.
2. Yamaya M, Yanai M, Ohrui T, et. al. Interventions to prevent pneumonia among older adults. J Am Geriatr Soc 2001; 49: 85-90. (Pubitemid 32195140)
3. Nagamine T. Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics. Neuropsychiatr Dis Treat 2008; 4: 289-294.
4. Xu M, Moratalla R, Gold LH, et al. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 1994; 79: 729-742. (Pubitemid 24363815)
5. Wang JQ, McGinty JF. The full D1 dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D1/D2 interactions by muscarinic receptors. J Pharmacol Exp Ther 1997; 281: 972-982.
6. Arai T, Yasuda Y, Takaya T, et. al. ACE inhibitors and symptomless dysphagia. Lancet 1998; 352: 115-116.